Prescription medication · Disease-Modifying Antirheumatic Drug (DMARD)
leflunomide
Also sold as Arava. Leflunomide treats active rheumatoid arthritis in adults.
Data updated 2026-05-15
- 102,095
- FDA reportsOften reported
- 20
- InteractionsSeveral interactions
- $0.31
- Generic price (NADAC)
What the data shows
leflunomide (Arava) is a prescription Disease-Modifying Antirheumatic Drug (DMARD), more reported than most tracked drugs (102,095 FDA reports), with 20 documented drug interactions.
Reporting volume reflects how widely a drug is used and studied, not how dangerous it is, a FAERS report documents a temporal association, never proof of cause.
leflunomide (Arava) is a prescription Disease-Modifying Antirheumatic Drug (DMARD). Leflunomide treats active rheumatoid arthritis in adults.
Leflunomide is a drug that can help reduce the symptoms of rheumatoid arthritis. It works by slowing down the body's immune system.
Verify with FDA → · CMS NADAC pricing →
Drug Pricing (NADAC)
Generic Price
$0.31/unit
Generic Available
Yes (8 manufacturers)
Pricing data from NADAC (CMS), effective December 18, 2024. Compare all drug costs →
NADAC price trail: LEFLUNOMIDE 10 MG TABLET
Same CMS presentation as the headline generic unit price above (2 effective dates). Adjacent % compares consecutive NADAC releases for this description only, not a patient out-of-pocket quote. Latest step: -5.2% vs prior release.
| Effective | NADAC / unit | vs prior | NDCs |
|---|---|---|---|
| July 17, 2024 | $0.3270/EA | - | 1 |
| December 18, 2024 | $0.3100/EA | -5.2% | 10 |
What it does
Leflunomide treats active rheumatoid arthritis in adults.
Common side effects
Diarrhea, Respiratory infection, Nausea
Key warnings
This drug can cause serious harm to an unborn baby.
The sections below are summarized in plain English from leflunomide's FDA-approved prescribing information. They describe what the official label says, and are not personal medical advice.
How It Works
Leflunomide is a pyrimidine synthesis inhibitor. This means it blocks a certain process in your body. By blocking this process, it can reduce inflammation and slow down the damage to your joints.
Side Effects (from patient reports)
Based on 102,095 FDA adverse event reports.
Most-reported reactions
Adverse reactions in FAERS for leflunomide, by number of reports
- Rheumatoid Arthritis
Rheumatoid Arthritis
24,923 reports
- Pain
Pain
20,055 reports
- Arthralgia
Arthralgia
16,941 reports
- Joint Swelling
Joint Swelling
15,567 reports
- Fatigue
Fatigue
15,384 reports
- Rash
Rash
13,321 reports
- Abdominal Discomfort
Abdominal Discomfort
11,731 reports
- Alopecia
Alopecia
11,692 reports
- Contraindicated Product Administered
Contraindicated Product Administered
11,637 reports
- Arthropathy
Arthropathy
10,791 reports
What this shows Bars show how often each reaction was reported, not how likely it is to happen, a report records a temporal association, never proof that the drug caused it.
Reports over time
Adverse-event reports filed for leflunomide each year to the FDA Adverse Event Reporting System (FAERS).
Year-to-year volume tracks usage, prescribing, and scrutiny, not a change in per-patient risk. Source: FDA FAERS.
Where leflunomide sits
leflunomide has more FDA adverse-event reports than 85% of the drugs FAERS tracks. A high position reflects how widely a drug is used and watched, not how dangerous it is.
Percentile across all drugs PlainMeds tracks by FAERS report volume. The dot is leflunomide; the line is the median (50th percentile).
FDA Adverse Event Report Analysis
Detailed analysis of 102,095 reports from the FDA Adverse Event Reporting System (FAERS). Reports span 2004–2025.
Total Reports
102,095
Reports Mentioning Death
8,456
8.3% of reports — not proof of cause
Hospitalization Reports
27,652
Top Indication
Rheumatoid Arthritis
Gender Distribution
Age Distribution
Most Reported Adverse Reactions (FAERS)
| # | Reaction | Reports |
|---|---|---|
| 2 | RHEUMATOID ARTHRITIS | 24,923 |
| 3 | PAIN | 20,055 |
| 4 | ARTHRALGIA | 16,941 |
| 6 | JOINT SWELLING | 15,567 |
| 7 | FATIGUE | 15,384 |
| 8 | RASH | 13,321 |
| 10 | ABDOMINAL DISCOMFORT | 11,731 |
| 11 | ALOPECIA | 11,692 |
| 12 | CONTRAINDICATED PRODUCT ADMINISTERED | 11,637 |
| 13 | ARTHROPATHY | 10,791 |
| 14 | CONDITION AGGRAVATED | 10,367 |
| 15 | SWELLING | 10,250 |
| 16 | NAUSEA | 10,126 |
| 17 | SYNOVITIS | 10,026 |
| 18 | SYSTEMIC LUPUS ERYTHEMATOSUS | 9,625 |
Reactions in Death Reports
Reactions in Hospitalization Reports
Source: FDA FAERS (Adverse Event Reporting System) Reports are voluntary and do not establish causation
Serious Warnings
This drug can cause serious harm to an unborn baby. If you are pregnant or could become pregnant, you should not take this medicine. This drug can also cause serious liver problems. If you have liver problems, you should not take this medicine. Your doctor will monitor your liver with blood tests.
Known Drug Interactions
For other substrates of BCRP (e.g., mitoxantrone) and drugs in the OATP family (e.g., methotrexate, rifampin), especially HMG-Co reductase inhibitors (e.g., atorvastatin, nateglinide, pravastatin, repaglinide, and simvastatin), consider reducing the dose of these drugs and monitor patients closely for signs and symptoms of increased exposures to the drugs while patients are taking leflunomide [see Clinical Pharmacology (12.3) ].
Mechanism: Leflunomide can interfere with how your body moves and clears atorvastatin, potentially leading to higher levels of the drug in your blood.
For a patient taking leflunomide, the dose of rosuvastatin should not exceed 10 mg once daily. ( 7 ) Rosuvastatin: The dose of rosuvastatin should not exceed 10 mg once daily in patients taking leflunomide.
Mechanism: Leflunomide changes how your body processes rosuvastatin, which can cause the amount of the cholesterol medicine in your blood to increase.
For other substrates of BCRP (e.g., mitoxantrone) and drugs in the OATP family (e.g., methotrexate, rifampin), especially HMG-Co reductase inhibitors (e.g., atorvastatin, nateglinide, pravastatin, repaglinide, and simvastatin), consider reducing the dose of these drugs and monitor patients closely for signs and symptoms of increased exposures to the drugs while patients are taking leflunomide [see Clinical Pharmacology (12.3) ].
Mechanism: Leflunomide can block the proteins that help your body get rid of simvastatin, which may cause the drug to reach higher levels than normal.
In patients taking leflunomide, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.
Mechanism: Leflunomide interferes with a protein that helps the body remove furosemide, which can cause the levels of furosemide in your blood to rise.
In patients taking leflunomide, exposure of drugs metabolized by CYP1A2 (e.g., alosetron, duloxetine, theophylline, tizanidine) may be reduced.
Mechanism: Leflunomide speeds up how fast your body breaks down duloxetine, which can lower the amount of medicine in your system and make it less effective.
This is a plain-language summary of FDA-label interaction records and does not provide individual medication-combination directions.
Common Questions
What should I do before starting leflunomide?
How long does it take for leflunomide to work?
Can I take other medicines with leflunomide?
What if I want to get pregnant while taking leflunomide?
How often will my liver be checked?
What are the signs of liver problems?
What if I get an infection?
Can leflunomide affect my blood pressure?
What happens if I need surgery?
What do the tablets look like?
What are the common side effects of leflunomide?
Does leflunomide interact with other medications?
What drug class is leflunomide?
What pregnancy or breastfeeding source fields are listed for leflunomide?
Related Medications in Disease-Modifying Antirheumatic Drug (DMARD)
Other drugs grouped near leflunomide - same-class peers and common alternatives.
abatacept
Orencia
Orencia is a medicine that helps to reduce inflammation.
Compare with leflunomide →
acetaminophen
Tylenol
Acetaminophen (Tylenol) is a medicine that can relieve pain and reduce fever.
Compare with leflunomide →
acetaminophen/hydrocodone
Vicodin, Norco
This medicine contains acetaminophen and hydrocodone.
Compare with leflunomide →
acetaminophen/oxycodone
Percocet
Percocet is a strong pain medicine.
Compare with leflunomide →
adalimumab
Humira
Idacio is a medicine that blocks a protein called TNF.
Compare with leflunomide →
Compare beyond drug class
Nationwide peers by FAERS volume & death-report share
Two PlainMeds-derived comparison paths for leflunomide: nearest FDA FAERS report volume and nearest death-report share among drugs with at least 1,000 logged reports, excluding same-class neighbors listed above. Counts reflect reporting volume, not proven individual harm.
Similar FAERS report volume
Nearest drugs by total FAERS reports. This record: 102,095.
- valsartan Δ 211 reports · Angiotensin II Receptor Blocker (ARB) 102,306reports
- ondansetron Δ 1,259 reports · 5-HT3 Receptor Antagonist (Antiemetic) 103,354reports
- olanzapine Δ 1,261 reports · Atypical Antipsychotic 103,356reports
- loratadine Δ 2,283 reports · Second-Generation Antihistamine 104,378reports
Similar death-report share
Nearest drugs by FAERS death-report share. This record: 8.28%.
- levomilnacipran Δ 0.01 pts · 1,858 reports · Serotonin-Norepinephrine Reuptake Inhibitor (SNRI) 8.29%death share
- lithium Δ 0.01 pts · 24,367 reports · Mood Stabilizer 8.29%death share
- acarbose Δ 0.02 pts · 3,736 reports · Alpha-Glucosidase Inhibitor 8.30%death share
- methimazole Δ 0.02 pts · 7,411 reports · Anti-Thyroid Agent 8.30%death share
Medication Guides
Understanding Drug Interactions
How CYP450 enzymes, inhibitors, and inducers affect your medications
Generic vs Brand Name Drugs
FDA requirements, cost savings, and when the difference matters
Narrow Therapeutic Index Drugs
FDA bioequivalence and label-record context for narrow therapeutic index medicines
Common Drug Interactions
Dangerous medication combinations and how to protect yourself
Save on leflunomide
Compare prices and find discounts at pharmacies near you. Free coupons can save up to 80% on prescriptions.
Disclosure: This link may earn us a commission at no extra cost to you. See our terms.
What the FDA Data Shows for leflunomide
The FDA label for leflunomide (sold under brand names such as Arava) classifies it as a prescription-only medication in the Disease-Modifying Antirheumatic Drug (DMARD) class. Leflunomide treats active rheumatoid arthritis in adults. Official labeling lists 7 commonly reported side effects, including Diarrhea, Respiratory infection, Nausea.
Post-market surveillance from the FDA Adverse Event Reporting System (FAERS) captures real-world experience. For this drug, FAERS contains 102,095 voluntary reports. The database also lists 20 documented drug interactions derived from FDA labeling, with the top-flagged interaction rated minor severity. NADAC pricing from CMS shows a generic unit cost of $0.31.
Report counts do not establish causation, a FAERS entry documents a temporal association, not proof that the drug produced the outcome. Widely prescribed medications naturally accumulate more reports than niche therapies, so raw totals must be interpreted alongside total exposure. Shortage status, recall history, and patent information are separate source-record fields. This page is a public FDA/CMS registry and does not provide medical, treatment, substitution, or medication-change directions.
Data Sources
Drug labeling: FDA Drug Labels (SPL/DailyMed). Adverse events: FDA Adverse Event Reporting System (FAERS). Pricing: CMS National Average Drug Acquisition Cost (NADAC).
FAERS reports are voluntary and do not establish causation. Drug interactions are derived from FDA labeling and clinical references. This registry does not provide medication decisions.
Last updated: December 17, 2025
PlainMeds is rendered directly from FDA openFDA/FAERS extracts, DailyMed labels, and CMS drug-pricing files, no number is typed in by an editor. FAERS counts, recalls, shortages, and price figures on this page are queried live from those federal extracts. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-05-15. Primary sources: openFDA / FAERS, DailyMed and CMS Part B ASP.
Read our methodology - how this data is sourced, computed, and verified.
Data currency: FDA FAERS adverse-event reports through 2025, CMS NADAC acquisition-cost pricing effective December 2024, compiled from the source snapshot dated . See our methodology for per-source dates and refresh cadence. Spot a figure that looks wrong? Report a data issue.
All federal data sources used on this page
- FDA Orange Book - approved drug products with therapeutic equivalence. accessdata.fda.gov/cder/ob
- FDA DailyMed - NIH-hosted drug labeling for FDA-approved meds. dailymed.nlm.nih.gov
- FDA Adverse Event Reporting System (FAERS) - post-marketing safety surveillance. fda.gov/drugs/faers
- NLM RxNorm - standardized clinical drug nomenclature. nlm.nih.gov/research/umls/rxnorm
- CMS Medicare Part B Drug Average Sales Price Files - federal drug pricing data. cms.gov/medicare/part-b-drugs/asp
- FDA Drug Shortages Database - current and resolved drug shortage tracking. accessdata.fda.gov/drugshortages